Cipla Ltd.

NSE: CIPLA | BSE: 500087 | ISIN: INE059A01026 | Industry: Pharmaceuticals
| Mid-range Performer
1502.4000 -11.40 (-0.75%)
NSE Jun 27, 2025 15:31 PM
Volume: 1.9M
 

logo
Cipla Ltd.
20 Apr 2020
1502.40
-0.75%
ICICI Securities Limited
On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....
Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.
More from Cipla Ltd.
Recommended